Arkolith/Insider Trading/PTGX/Form 4

Waddill William D.

DirectorProtagonist Therapeutics, Inc (PTGX) · full profile →Form 4 · filed Jun 1, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$897K
Net Open-Market Flow
-$897K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 29, 2026Option exercise(M)9K$11.80$106K17K
May 29, 2026Sell(S)9K$99.64$897K8K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 29, 2026Option exercise(M)9K—$03K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-26-069047) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML